Actos, Takeda's new once-daily thiazolidinedione for type 2 diabetes that was approved in mid-July, is currently in distribution. The company is fine-tuning marketing and education efforts to begin this fall, with a focus on pharmacist education--including CE programs for later this year-and exploring the climate toward disease state management/patient education initiatives, according to Rich Daley, director of marketing at Takeda. The company is marketing the drug with Eli Lilly in what will be when combined the largest dedicated diabetes sales force in the United States.
"We see the pharmacy community as a real partner here," said Daley. 'We're excited about the opportunity to work with one of the primary caregivers, such as pharmacists on a drug like Actos. You can create whatever kinds of patient education you want," he said.
"We see pharmacists are our partners in education and that will be a focus for us. On a chronic disease such as diabetes you can't have enough patient education," Daley continued, "and that doesn't just come in the form of brochures. Hearing information from a healthcare professional--and a primary healthcare professional, such as the pharmacist--is a tremendously successful way of impacting patients and care. I believe having a good understanding of what pharmacists believe to be important for patient care is fundamental for us."
Takeda also plans consumer-oriented programs.
COPYRIGHT 1999 Lebhar-Friedman, Inc.
COPYRIGHT 2000 Gale Group
Contact
Home
A
8-Hour Bayer